{"title":"不同剂量厄图列净治疗2型糖尿病的有效性和安全性的网络meta分析","authors":"Z. Qian, Sang Yafei, Lijing Shang, Ma Yujin","doi":"10.25236/FMSR.2021.030407","DOIUrl":null,"url":null,"abstract":"Objective: To conduct a network meta-analysis to systematically evaluate the efficacy and safety of different doses of ertugliflozin in the treatment of Type 2 diabetes. Methods: The Pubmed, Embase, Cochrane library, CNKI, Wanfang, Weipu, CBM, Web of science and other daTableases were searched by computer from the beginning of the daTablease to 2021. To search for randomized controlled trial of different doses of ertugliflozin in the treatment of type 2 diabetes, to screen the literature according to inclusion and exclusion criteria, to extract data, and to evaluate the quality of the included studies by Cochrane systematic evaluation methods,using RevMan5.3 software and Stata 16.0 versions for analysis. RESULTS: A total of 11 randomized controlled trials (RCTs) were enrolled, including 5713 patients, The results of network meta-analysis showed that ertugliflozin 5,10,15,25 mg were superior to placebo in reducing glycosylated hemoglobin, Only 15 mg was statistically significant(p","PeriodicalId":129141,"journal":{"name":"Frontiers in Medical Science Research","volume":"423 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A network meta-analysis of the effectiveness and safety of different doses of ertugliflozin in the treatment of type 2 diabetes\",\"authors\":\"Z. Qian, Sang Yafei, Lijing Shang, Ma Yujin\",\"doi\":\"10.25236/FMSR.2021.030407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To conduct a network meta-analysis to systematically evaluate the efficacy and safety of different doses of ertugliflozin in the treatment of Type 2 diabetes. Methods: The Pubmed, Embase, Cochrane library, CNKI, Wanfang, Weipu, CBM, Web of science and other daTableases were searched by computer from the beginning of the daTablease to 2021. To search for randomized controlled trial of different doses of ertugliflozin in the treatment of type 2 diabetes, to screen the literature according to inclusion and exclusion criteria, to extract data, and to evaluate the quality of the included studies by Cochrane systematic evaluation methods,using RevMan5.3 software and Stata 16.0 versions for analysis. RESULTS: A total of 11 randomized controlled trials (RCTs) were enrolled, including 5713 patients, The results of network meta-analysis showed that ertugliflozin 5,10,15,25 mg were superior to placebo in reducing glycosylated hemoglobin, Only 15 mg was statistically significant(p\",\"PeriodicalId\":129141,\"journal\":{\"name\":\"Frontiers in Medical Science Research\",\"volume\":\"423 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medical Science Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25236/FMSR.2021.030407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medical Science Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25236/FMSR.2021.030407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:通过网络荟萃分析，系统评价不同剂量厄图列净治疗2型糖尿病的疗效和安全性。方法:计算机检索Pubmed、Embase、Cochrane library、CNKI、万方、唯普、CBM、Web of science等数据库自daTablease开始至2021年。检索不同剂量厄图格列净治疗2型糖尿病的随机对照试验，按照纳入和排除标准筛选文献，提取资料，采用Cochrane系统评价方法评价纳入研究的质量，采用RevMan5.3软件和Stata 16.0版本进行分析。结果:共纳入11项随机对照试验(RCTs)，共纳入5713例患者。网络荟萃分析结果显示，厄图列净5、10、15、25 mg在降低糖化血红蛋白方面均优于安慰剂，只有15 mg具有统计学意义(p < 0.05)
A network meta-analysis of the effectiveness and safety of different doses of ertugliflozin in the treatment of type 2 diabetes
Objective: To conduct a network meta-analysis to systematically evaluate the efficacy and safety of different doses of ertugliflozin in the treatment of Type 2 diabetes. Methods: The Pubmed, Embase, Cochrane library, CNKI, Wanfang, Weipu, CBM, Web of science and other daTableases were searched by computer from the beginning of the daTablease to 2021. To search for randomized controlled trial of different doses of ertugliflozin in the treatment of type 2 diabetes, to screen the literature according to inclusion and exclusion criteria, to extract data, and to evaluate the quality of the included studies by Cochrane systematic evaluation methods,using RevMan5.3 software and Stata 16.0 versions for analysis. RESULTS: A total of 11 randomized controlled trials (RCTs) were enrolled, including 5713 patients, The results of network meta-analysis showed that ertugliflozin 5,10,15,25 mg were superior to placebo in reducing glycosylated hemoglobin, Only 15 mg was statistically significant(p
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
